Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
about
Preparing for dengue vaccine introduction: recommendations from the 1st dengue v2V International MeetingControlling dengue with vaccines in ThailandMechanism and significance of cell type-dependent neutralization of flavivirusesTackling dengue fever: Current status and challengesThe global distribution and burden of dengueGlobal spread of dengue virus types: mapping the 70 year historyDiscovery of fifth serotype of dengue virus (DENV-5): A new public health dilemma in dengue controlStructural basis of potent Zika–dengue virus antibody cross-neutralizationRapid and Non-destructive Detection and Identification of Two Strains of Wolbachia in Aedes aegypti by Near-Infrared SpectroscopyDengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika VirusPotent Allosteric Dengue Virus NS5 Polymerase Inhibitors: Mechanism of Action and Resistance ProfilingZika virus disease: a current review of the literatureHuman antibody response to dengue virus: implications for dengue vaccine designThe dengue vaccine pipeline: Implications for the future of dengue controlDengue vaccine: a valuable asset for the futureThe Cellular Bases of Antibody Responses during Dengue Virus InfectionDengue Fever: Causes, Complications, and Vaccine StrategiesSafety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical TrialsStructure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant EpitopeBenefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deploymentGuiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccineSystems Biology Approach for Cancer Vaccine Development and EvaluationIntroducing a dengue vaccine to Mexico: development of a system for evidence-based public policy recommendationsA critical assessment of vector control for dengue preventionRecent Advances in Dengue: Relevance to Puerto RicoReviewing dengue: still a neglected tropical disease?The yellow fever 17D virus as a platform for new live attenuated vaccinesThe Complexity of a Dengue Vaccine: A Review of the Human Antibody ResponseVaccines for the 21st centuryDengue: Moving from Current Standard of Care to State-of-the-Art TreatmentUnderstanding the dengue viruses and progress towards their controlVaccine-mediated immunity against dengue and the potential for long-term protection against diseaseLatest developments and future directions in dengue vaccinesEarly Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human PrimatesDengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral SerotypesThe Spread of Dengue in an Endemic Urban Milieu--The Case of Delhi, IndiaRational design of a live attenuated dengue vaccine: 2'-o-methyltransferase mutants are highly attenuated and immunogenic in mice and macaquesImmunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trialDengue structure differs at the temperatures of its human and mosquito hostsCell-targeting antibodies in immunity to Ebola
P2860
Q21562244-BFEB1F0E-0277-42CB-B4C5-E2EDC58193A2Q21562250-D92120B0-E0A9-4128-9705-CE3E6081BDBAQ23032973-F10B5294-8D00-4B65-AFCA-BED1CD9D2E11Q24288867-76218603-A802-49E3-97AF-635948AB5FE7Q24628768-AD090F89-9700-4FFB-ADC9-50AA9AF68027Q24736362-1D018D8D-3F83-4D1D-A272-CDD2FABBC3A0Q24736845-74D5CCAF-C02B-4088-8796-B3A9337B3A11Q24740325-992A6CF0-D838-424D-8347-D74D67FC6CDDQ25202252-67FF2865-CDC0-412B-8F18-31599259B15AQ26247258-8050722E-9092-4E8E-BA26-5101B17C0C7EQ26247399-D3A4E6C2-44F5-453E-A9E6-76C4C6215582Q26261644-AF154972-976E-4849-8C41-5A4AE0EE507FQ26314609-F4D2B193-EC69-4F17-B264-ED4CED4C58B1Q26314683-98B2BA25-8A76-44A5-B4B9-210791F7F456Q26314686-784E1FBF-6951-4079-A6C8-B08BB703A69CQ26700056-910D9B65-993E-4363-B566-6F5BC7F539EBQ26700082-14AF9814-E501-477E-A408-5CBE7DA6DF56Q26700096-D2259E82-457D-4CC3-B88E-ACF564810EA7Q26700120-9670E6A0-085B-454D-9600-A347FAAC7851Q26746185-B477C2B4-33E6-4182-A135-553DB7597B6CQ26782367-57BE9029-A1B6-48B3-B8A4-E3B50780D8C5Q26782580-B545F8F4-E048-420D-BD5B-36FA29F066A4Q26823330-3CFA5384-F7EC-4F02-B08F-8A602605F200Q26824776-0D391087-7240-4073-9D8A-0516A93596A0Q26825426-629F9956-9161-4C97-B838-9B12153AECC8Q26825672-8409E5B2-D585-49EE-8833-6B8E70997155Q26865102-6889E830-3389-47FB-AA60-08EBA00657BDQ26995782-EBC336F7-3D6E-4590-BEFF-7452223CC695Q27007529-D94B4E51-62D5-4447-AB14-60A61CAF686BQ27010609-4FB80FD1-9B97-4C92-BE98-28323BCEB1ABQ27011587-DB47567A-6DB0-4229-BBC9-361DA216475DQ27014663-61D2DFCC-3C32-4FDF-AA8A-BCC624C4F659Q27023422-832D9D93-7728-4130-8200-F3136CADB739Q27303669-E2C6B56D-0FF5-4AB4-B493-EAED7C4D09F5Q27304342-934E314C-7BE5-4859-9C18-E25FF88A74B1Q27332223-1F243F9B-7989-4652-AFED-E9CA975E5FA2Q27334248-F7157B1B-3342-4C62-A278-77CAE9F55E15Q27468578-B85B2BF5-ECB5-40BA-9793-E73ABB22BEE2Q27677270-814981DE-AFCC-4B85-B210-0726B31905D0Q28068972-426616C1-1C20-4D3B-A55A-19C59CA85BA7
P2860
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Protective efficacy of the rec ...... sed, controlled phase 2b trial
@ast
Protective efficacy of the rec ...... sed, controlled phase 2b trial
@en
type
label
Protective efficacy of the rec ...... sed, controlled phase 2b trial
@ast
Protective efficacy of the rec ...... sed, controlled phase 2b trial
@en
prefLabel
Protective efficacy of the rec ...... sed, controlled phase 2b trial
@ast
Protective efficacy of the rec ...... sed, controlled phase 2b trial
@en
P2093
P921
P3181
P1433
P1476
Protective efficacy of the rec ...... sed, controlled phase 2b trial
@en
P2093
Bouckenooghe A
Chanthavanich P
Dulyachai W
Jiwariyavej V
Limkittikul K
Sabchareon A
P304
P3181
P356
10.1016/S0140-6736(12)61428-7
P407
P5008
P577
2012-11-03T00:00:00Z